Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib + 7+3 + Midostaurin in Frontline NPM1 and FLT3 Mutated AML
NCT06313437Phase 1Recruiting
- Start
- Dec 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of revumenib in acute myeloid leukemia (AML) (2 arms). Primary endpoints: Dose Limiting Toxicity at 12 weeks, Maximum Tolerated Dose at 12 weeks and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06313437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313437.